help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by D'Ercole, A. J.
Right arrow Articles by Kortleve, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by D'Ercole, A. J.
Right arrow Articles by Kortleve, D. J.

Journal of Clinical Endocrinology & Metabolism, Vol 61, 612-617, Copyright © 1985 by Endocrine Society


ARTICLES

Somatomedin-C/insulin-like growth factor I-binding proteins in human amniotic fluid and in fetal and postnatal blood: evidence of immunological homology

AJ D'Ercole, SL Drop and DJ Kortleve

By using the chemical cross-linking agent dis-succinimidyl suberate and [125I]somatomedin-C/insulin-like growth factor I (Sm-C/IGF-I) to affinity label Sm-binding proteins, we identified a 30,000- to 40,000- dalton (30-40K) [125I] Sm-C-binding protein complex in midterm amniotic fluid and cord blood. An antibody raised against a Sm-binding protein purified from midterm amniotic fluid recognized this labeled complex not only in amniotic fluid but also in fetal serum and term cord and several postnatal human plasmas, indicating that the 30-40K Sm-binding proteins in each are similar or identical. The binding proteins in amniotic fluid appear to possess binding sites specific for Sm-C, because under the conditions employed, unlabeled Sm-C was at least 10- fold more potent than IGF-II or multiplication-stimulating activity in competing with [125I]Sm-C for binding. Although [125I]GF-II could be cross-linked to similarly sized proteins, unlabeled Sm-C also competed for this binding better than either unlabeled IGF-II or MSA (at least 5- fold greater potency). These findings suggest that this amniotic fluid Sm-binding protein is primarily a carrier of Sm-C, but does not exclude the possibility that a binding site or a distinct binding protein exists which is specific for IGF-II but not amenable to cross-linking by the procedure used. Because unlabeled Sm-C was less potent in inhibiting the binding of [125I]Sm-C to amniotic fluid than to cord plasma proteins, the amniotic fluid binding protein is either more abundant or less avidly binds [125I]Sm-C than the cord plasma binding protein.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
M. J. Khosravi, A. Diamandi, J. Mistry, R. G. Krishna, and A. Khare
Acid-Labile Subunit of Human Insulin-Like Growth Factor-Binding Protein Complex: Measurement, Molecular, and Clinical Evaluation
J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 3944 - 3951.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1985 by The Endocrine Society